Literature DB >> 11346322

Health-related quality of life and health care costs in severe, refractory irritable bowel syndrome.

F Creed1, J Ratcliffe, L Fernandez, B Tomenson, S Palmer, C Rigby, E Guthrie, N Read, D Thompson.   

Abstract

BACKGROUND: The irritable bowel syndrome (IBS) may lead to considerable impairment of health-related quality of life and high health care costs. It is not clear whether these poor outcomes directly result from severe bowel symptoms or reflect a coexisting psychiatric disorder.
OBJECTIVE: To determine whether bowel symptom severity and psychological symptoms directly influence health-related quality of life and health care costs.
DESIGN: Cross-sectional survey.
SETTING: Secondary and tertiary gastroenterology clinics. PATIENTS: 257 patients with severe IBS who did not respond to usual treatments and were recruited for a trial of psychological treatment. MEASUREMENTS: Predictors were abdominal pain, entries in a diary of 10 IBS symptoms, and measures of psychological symptoms. Outcomes were inability to work, health-related quality of life (measured by Medical Outcomes Survey 36-item short-form questionnaire [SF-36] physical component summary scores), and health care and productivity costs. Predictor and outcome measures were compared by using multiple regression and logistic regression analyses.
RESULTS: Abdominal pain occurred on average 24 days per month and activities were restricted on 145 days of the previous 12 months. The mean (+/-SD) Hamilton depression score was 11.3 +/- 6.1. The SF-36 physical component summary score was low (37.7 +/- 10.6), and the patients had incurred high health care costs ($1743 +/- $2263) over the previous year. Global severity and somatization scores on the Symptom Checklist 90 Revised, abdominal pain, and Hamilton depression scores independently contributed to the physical component score of the SF-36 (adjusted R(2) = 35.2%), but only psychological scores were associated with disability due to ill health. These variables did not accurately predict health care or other costs (adjusted R(2) = 9.3%). History of sexual abuse was not an independent predictor of outcome.
CONCLUSIONS: Both abdominal and psychological symptoms are independently associated with impaired health-related quality of life in patients with severe IBS. Optimal treatment is likely to require a holistic approach. Since health care and loss of productivity costs are not clearly associated with these symptoms, alleviation of them will not necessarily lead to reduced costs.

Entities:  

Mesh:

Year:  2001        PMID: 11346322     DOI: 10.7326/0003-4819-134-9_part_2-200105011-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  63 in total

1.  What level of IBS symptoms drives impairment in health-related quality of life in community subjects with irritable bowel syndrome? Are current IBS symptom thresholds clinically meaningful?

Authors:  Natasha A Koloski; Philip M Boyce; Michael P Jones; Nicholas J Talley
Journal:  Qual Life Res       Date:  2011-08-11       Impact factor: 4.147

2.  Linaclotide: a novel therapy for chronic constipation and constipation-predominant irritable bowel syndrome.

Authors:  Brian E Lacy; John M Levenick; Michael D Crowell
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-10

3.  The treatment of irritable bowel syndrome.

Authors:  Brian E Lacy; Kirsten Weiser; Ryan De Lee
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

Review 4.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

Review 5.  Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome.

Authors:  Pejman Katiraei; Gilberto Bultron
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

Review 6.  Common Functional Gastroenterological Disorders Associated With Abdominal Pain.

Authors:  Adil E Bharucha; Subhankar Chakraborty; Christopher D Sletten
Journal:  Mayo Clin Proc       Date:  2016-08       Impact factor: 7.616

7.  So-eum type as an independent risk factor for irritable bowel syndrome: a population-based study in Korea.

Authors:  Seung Ku Lee; Dae Wui Yoon; Hyeryeon Yi; Si Woo Lee; Jong Yeol Kim; Jin Kwan Kim; Jeong Hwa Hong; Chol Shin
Journal:  J Altern Complement Med       Date:  2014-08-22       Impact factor: 2.579

Review 8.  New developments in the diagnosis and treatment of irritable bowel syndrome.

Authors:  George F Longstreth; Douglas A Drossman
Journal:  Curr Gastroenterol Rep       Date:  2002-10

9.  How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice.

Authors:  Per A Johansson; Per G Farup; Andrea Bracco; Per O Vandvik
Journal:  BMC Gastroenterol       Date:  2010-03-17       Impact factor: 3.067

10.  The association of mast cells and serotonin in children with chronic abdominal pain of unknown etiology.

Authors:  Tara J Taylor; Nader N Youssef; Ravi Shankar; David E Kleiner; Wendy A Henderson
Journal:  BMC Res Notes       Date:  2010-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.